- Details
- Zachary Klaassen is joined by Daniel Spratt to discuss data comparing the 22-gene Decipher® genomic classifier and digital pathology artificial intelligence in nearly 10,000 localized prostate cancer patients. Dr. Spratt highlights findings that both biomarkers independently predict distant metastasis, with the combination yielding the strongest prognostic model. In multivariable analysis, only th...
|
- Details
- Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics. Their study reveals that while both high Decipher® scores and high-risk MRI findings independently predict progression, these markers are weakly correlated, suggesting they capture distinct risk information. The conversati...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
|
- Details
- Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...
|
- Details
- Preston Sprenkle and Randy Vince join Ashley Ross to discuss active surveillance and the benefits of risk stratification for localized prostate cancer. They collectively emphasize the importance of monitoring cancer closely and intervening with curative intent if it becomes aggressive while minimizing morbidity and improving quality of life. Dr. Vince highlights the Michigan Urological Surgery Imp...
|
- Details
- Katie Murray and Anne Lizardi-Calvaresi discuss a clinical pathway approach for using the Decipher prostate cancer genomic classifier. Reviewing the level-one evidence described in the NCCN guidelines, they discuss best practices as clinicians integrate prostate cancer genomic classifiers into the care of their patients. They highlight how the test is integrated into the workflow for patient navig...
|
- Details
- Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....
|
- Details
- Alicia Morgans and Ashley Ross discuss Decipher® testing, both Decipher® Biopsy and Decipher® for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher® is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to st...
|
- Details
- Daniel Spratt and Randy Vince discuss the impact of Decipher® Biopsy testing on clinical outcomes in localized prostate cancer. This conversation starts off with a background on Decipher® Biopsy testing and how it is used for men with prostate cancer. This then transitions into a discussion on the controls and background of how the study was set up. Dr. Vince then discusses some of the main findin...
|
